Retatrutide

Retatrutide 5 mg — the triple-agonist frontier of metabolic peptide research
A single-molecule triple receptor agonist that has pushed metabolic research past the two-receptor era. Retatrutide is one of the most closely watched investigational Peptides in current energy-balance literature, and this vial delivers it as batch-tested, pharmaceutical-grade lyophilised powder.

What is Retatrutide?

Retatrutide is a synthetic, multi-agonist peptide engineered to interact with three distinct incretin and metabolic receptors at once: GLP-1, GIP and the glucagon receptor. Where earlier research peptides in this class engage one or two of those targets, Retatrutide's interest to researchers lies precisely in the combination — the glucagon arm is studied for its relationship to energy expenditure, while the GLP-1 and GIP arms are examined in the context of appetite signalling and nutrient handling. That layered receptor profile is why it is repeatedly referenced in investigations of body-composition regulation and integrated metabolic control.

Research interest

• Multi-receptor pharmacology — used as a tool compound by researchers examining how simultaneous GLP-1, GIP and glucagon receptor engagement differs from single-target agonism.
• Energy balance — investigated in research contexts concerned with energy expenditure and substrate utilisation.
• Appetite and satiety signalling — of interest to groups studying incretin-mediated regulation of food intake in preclinical models.
• Body-composition research — referenced in literature examining shifts in fat and lean mass compartments.
• Receptor-crosstalk modelling — a reference peptide for studies mapping how converging metabolic signals interact downstream.

Because of its receptor breadth, Retatrutide is frequently used as a comparator in studies that benchmark newer multi-agonists against established single-pathway peptides. Material quality matters disproportionately here: receptor-binding and signalling assays are unforgiving of degraded or impure peptide, which is why every Rogue vial is lot-traceable.

Specifications

• Content: 5 mg of active substance per vial
• Form: Lyophilised powder (vial)
• Purity: Pharmaceutical-grade, batch-tested and lot-traceable
• Presentation: Sealed, tamper-evident single vial
• Storage: -20 °C sealed; 2-8 °C short-term

Handling & storage

Store sealed lyophilised vials at -20 °C for long-term stability; short periods at 2-8 °C are generally tolerated during transit and handling. Keep vials sealed, protected from light and away from moisture and repeated temperature swings. Reconstitution in a laboratory setting should follow the facility's own validated protocol using an appropriate sterile diluent; once in solution, peptide stability is reduced and refrigerated storage with minimal handling is standard practice. Always allow a frozen vial to equilibrate to room temperature before breaking the seal to prevent condensation on the lyophilisate.

Why source from Rogue

• Verified purity — every batch is identity- and purity-tested, with documentation traceable back to the production lot.
• European supply chain — sealed vials, authenticated manufacturing, never grey-market repackaging.
• Cold-aware logistics — protective packaging and fast, tracked dispatch across the EU.
• Discreet handling — plain outer packaging and full order confidentiality, from checkout to doorstep.

For research purposes only. Not a medicinal product. Not for human or veterinary consumption. Intended for qualified laboratory research use only. No statement on this page is a medical claim, and no administration, dosing or protocol guidance is offered or implied.

Related: Somatropin HGH 36 IU · Cagrilintide 5 mg